Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Edward B. Garon , Tudor‐Eliade Ciuleanu , Óscar Arrieta +23 more 2014 The Lancet 1263 citations